These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37383084)

  • 1. Transarterial chemoembolization using drug-eluting bead compared with radiofrequency ablation for treatment of single small hepatocellular carcinoma: a pilot non-randomized trial.
    Kim TH; Kim NH; Kim JD; Kim YN; Kim YJ; Kim EJ; Yoo KD; Ryu CH; Song HH; Kim H
    J Liver Cancer; 2021 Sep; 21(2):146-154. PubMed ID: 37383084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Eluting Bead Transarterial Chemoembolization Versus Radiofrequency Ablation as an Initial Treatment of Single Small (≤ 3 cm) Hepatocellular Carcinoma.
    Lee S; Jeong YY; Lee BC; Shin SS; Heo SH; Kim HO; Park C; Jeong WG
    J Korean Med Sci; 2023 Oct; 38(42):e362. PubMed ID: 37904659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients.
    Zhu D; Yuan D; Wang Z; Chen S
    Medicine (Baltimore); 2019 Jun; 98(26):e15682. PubMed ID: 31261491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparison of Adverse Events Among Radiofrequency Ablation, Conventional Transarterial Chemoembolization (TACE) and Drug-Eluting Bead TACE in Treating Hepatocellular Carcinoma Patients.
    Cao G; Liu Y; Li L; Zhao X; Liu R; Liu J; Liu J; Cao H
    Cancer Manag Res; 2021; 13():5373-5382. PubMed ID: 34262345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation.
    Vasnani R; Ginsburg M; Ahmed O; Doshi T; Hart J; Te H; Van Ha TG
    Hepatobiliary Surg Nutr; 2016 Jun; 5(3):225-33. PubMed ID: 27275464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation.
    Wang X; Liang H; Lu Z
    Minim Invasive Ther Allied Technol; 2020 Dec; 29(6):344-352. PubMed ID: 31375044
    [No Abstract]   [Full Text] [Related]  

  • 7. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
    Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
    World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Tang J; Huang Z; Xu J; Lv Q; Wang P
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tumor response following conventional versus drug-eluting bead transarterial chemoembolization in early- and very early-stage hepatocellular carcinoma.
    Razi M; Safiullah S; Gu J; He X; Razi M; Kong J
    J Interv Med; 2022 Feb; 5(1):10-14. PubMed ID: 35586278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma.
    Zhang Y; Zhang MW; Fan XX; Mao DF; Ding QH; Zhuang LH; Lv SY
    World J Gastrointest Surg; 2020 Aug; 12(8):355-368. PubMed ID: 32903981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
    Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression.
    Cao S; Zou Y; Lyu T; Fan Z; Guan H; Song L; Tong X; Wang J
    Int J Hyperthermia; 2022; 39(1):1-7. PubMed ID: 34937501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
    Adel H; Shazlee MK; Qamar S; Hyder SMS; Razaque A
    Cureus; 2023 Jul; 15(7):e41701. PubMed ID: 37575777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
    Tang C; Shen J; Feng W; Bao Y; Dong X; Dai Y; Zheng Y; Zhang J
    Medicine (Baltimore); 2016 May; 95(20):e3754. PubMed ID: 27196501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis.
    Guo J; Wang W; Zhang Y; Xu L; Kong J
    J Gastrointest Oncol; 2021 Aug; 12(4):1838-1850. PubMed ID: 34532132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: Focused on the recurrence patterns.
    Park W; Chung YH; Kim JA; Jin YJ; Lee D; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Lee YS; Kim PN; Sung KB
    Hepatol Res; 2013 Dec; 43(12):1304-12. PubMed ID: 23442052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Li C
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101535. PubMed ID: 33121882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.